Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
disitamab vedotin + PD-L1 inhibitor + GM-CSF + thymopentin
- Development stage
- Unknown
- Lead developer
- RemeGen
- Modality
- Peptides, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous, Intramuscular
01
Overview
ADC + PD-L1 + GM-CSF + thymopentin is a multi-component combination immunotherapy regimen evaluated in the PRaG9.0 Phase II clinical trial (NCT06112041) for elderly patients with HER2-positive advanced solid tumors. The regimen consists of the HER2-targeting antibody-drug conjugate (ADC) disitamab vedotin (RC48), a PD-L1 checkpoint inhibitor, the immunostimulatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), and the synthetic immunomodulatory peptide thymopentin. This regimen is an extension of the PRaG platform therapy, which typically incorporates hypofractionated radiotherapy to induce an in-situ vaccine effect. The combination is designed to provide targeted cytotoxic delivery to HER2-expressing tumor cells while simultaneously stimulating a systemic anti-tumor immune response through checkpoint blockade and immune effector cell activation.
- Other names
- PRaG 9.0 regimenPRaG9.0 regimenPRaG-9.0 regimenRC48 + PD-L1 inhibitor + GM-CSF + thymopentin
02
Targets
CSF2RB (Cytokine receptor common subunit beta)ERBB2 (Erb-b2 receptor tyrosine kinase 2)CD274 (Programmed cell death protein 1 ligand 1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on disitamab vedotin + PD-L1 inhibitor + GM-CSF + thymopentin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on disitamab vedotin + PD-L1 inhibitor + GM-CSF + thymopentin.